Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30130837 | 0.94 | DPP7 (0.48) | ALDH1A1SMN1; SMN2LMNAMAPTHRH2 | |
| SCHEMBL1295027 | 0.89 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2LMNAMAPTHRH2 | |
| SCHEMBL6097088 | 0.81 | MEN1 (0.53) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL12563933 | 0.81 | NR1H2 (0.52) | ALDH1A1SMN1; SMN2LMNAMAPTHRH2 | |
| SCHEMBL18585134 | 0.80 | LMNA (0.47) | ALDH1A1SMN1; SMN2LMNAMAPTHRH2 | |
| SCHEMBL8301729 | 0.80 | MGLL (0.64) | ALDH1A1SMN1; SMN2LMNAMAPTHRH2 | |
| SCHEMBL1945831 | 0.79 | TMEM97 (0.56) | SMN1; SMN2HRH2HRH1KMT2AMEN1 | |
| SCHEMBL6141536 | 0.79 | KMT2A (0.74) | ALDH1A1SMN1; SMN2LMNAMAPTHRH2 | |
| SCHEMBL27464372 | 0.79 | MAPT (0.79) | ALDH1A1SMN1; SMN2LMNAMAPTHRH2 | |
| SCHEMBL2306719 | 0.78 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676781-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-10 | — | — | US | disclosed |
| US-9062034-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-8981076-B2 | Synthesis of N-FMOC protected deoxy nucleosides, ribo nucleosides, modified deoxy and ribo nucleosides, and phosphoramidites, and their use in oligonucleotide synthesis | CHEMGENES CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | US | disclosed |
| EP-1487801-A1 | 7-ARYLSULFONAMIDO-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003068751-A1 | 7-ARYLSULFONAMIDO-2,3,4,5-TETRAHYDRO-1H-BENZO'DIAZEPINE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY FOR THE REATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| EP-0777667-A1 | CYCLIC BENZAZEPINE UREA DERIVATIVES WITH AGGREGATION-INHIBITING EFFECT | Dr. Karl Thomae GmbH (DE) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996005194-A1 | CYCLIC BENZAZEPINE UREA DERIVATIVES WITH AGGREGATION-INHIBITING EFFECT | DR. KARL THOMAE GMBH (DE) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GNMT | ALDH1A1 1039/4885SMN1; SMN2 3359/4885LMNA 2509/4885 |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GRM1 | ALDH1A1 871/4885SMN1; SMN2 3286/4885LMNA 2832/4885 |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GRM1 | ALDH1A1 871/4885SMN1; SMN2 3286/4885LMNA 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.